Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3081-3088

  Melo, Analy S ^a   Colombo, Arnaldo L ^a   Arthington Skaggs, Beth A ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; POLYSTYRENE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGAL METABOLISM; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; SPECIES;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; RISK; TETRAZOLIUM SALTS;

EID: 35848948735     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00676-07     Document Type: Article

References (28)

1. Baillie, G. S., and L. J. Douglas. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46:397-403.
2. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echninocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
3. Chandra, J., D. M. Kuhn, P. K. Mukherjee, L. L. Hoyer, T. McCormick, and M. A. Ghannoum. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394.
4. Clemons, K. V., M. Espiritu, R. Parmer, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
5. Cocuaud, C., M.-H. Rodier, G. Daniault, and C. Imbert. 2005. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 56:507-512.
6. Donlan, R. M. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8:1-19.
7. Donlan, R. M., and J. W. Costerton. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193.
8. Hawser, S. P., and L. J. Douglas. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62:915-921.
9. Jin, Y., H. K. Yip, Y. H. Samaranayake, J. Y. Yau, and L. P. Samaranayake. 2003. Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J. Clin. Microbiol. 41:2961-2967.
10. Kuhn, D. M., J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun. 70:878-888.
11. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
12. Kuhn, D. M., and M. A. Ghannoum. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.
13. Letscher-Bru, V., and R. Herbrecht. 2003. Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. 51:513-521.
14. Lin, D., L. C. Wu, M. G. Rinaldi, and P. F. Lehmann. 1995. Three distinct genotypes within Candida parapsilosis from clinical sources. J. Clin. Microbiol. 33:1815-1821.
15. Mermel, L. A., B. M. Farr, R. J. Sherertz, I. Raad, N. O'Grady, J. S. Harris, and D. E. Craven. 2001. Guidelines for management of intravascular catheter-related infections. Clin. Infect. Dis. 32:1249-1272.
16. Mukherjee, P. K., and J. Chandra. 2004. Candida biofilm resistance. Drug Resist. Updat. 7:301-309.
17. Nakai, T., T. Suzuki, I. M., K. Hatano, S. Matsumoto, F. Ikeda, and K. Maki. 2006. Paradoxical growth of Candida tropicalis in response to micafungin, abstr. M-1761, p. 435. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Nucci, M., and E. J. Anaissie. 2002. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin. Infect. Dis. 34:591-599.
20. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
21. Schinabeck, M. K., L. A. Long, M. A. Hossain, J. Chandra, P. K. Mukherjee, S. Mohamed, and M. A. Ghannoum. 2004. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob. Agents Chemother. 48:1727-1732.
22. Shuford, J. A., M. S. Rouse, K. E. Piper, J. M. Steckelberg, and R. Patel. 2006. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catherter infection model. J. Infect. Dis. 194:710-713.
23. Song, J. W., J. H. Shin, D. H. Shin, S. Jung, D. Cho, S. J. Kee, M. G. Shin, S. P. Suh, and D. W. Ryang. 2005. Differences in biofilm production by three genotypes of Candida parapsilosis from clinical sources. Med. Mycol. 43: 657-661.
24. Stanley, N. R., and B. A. Lazazzera. 2004. Environmental signals and regulatory pathways that influence biofilm formation. Mol. Microbiol. 52:917-924.
25. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
26. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin: evidence for B-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
27. Stevens, D. A., T. C. White, D. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178.
28. Tavanti, A., A. D. Davidson, N. A. Gow, M. C. Maiden, and F. C. Odds. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292.